RecruitingPhase 2

A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

United States56 participantsStarted 2025-02-05

Plain-language summary

This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease

Who can participate

Age range18 Years – 68 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Key Inclusion Criteria: * APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2 * Chronic kidney disease with persistent albuminuria Key Exclusion Criteria: * Organ or bone marrow transplantation * History of cancer within past 2 years, excepted for treated non-melanoma skin cancer, stage 0 cervical cancer, or stage 1 prostate cancer * Conditions that may alter drug absorption, e.g., history of bariatric surgery * Type I diabetes * Pregnant or currently nursing Other inclusion/exclusion criteria defined in protocol apply.

What they're measuring

Safety and tolerability as assessed by incidence of adverse events (AEs)

Timeframe: Day 1 to Week 12

Trial details

NCT IDNCT06830629

SponsorMaze Therapeutics

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-09

Contact for this trial

Maze Therapeutics

650-850-5075 APOL1info@mazetx.com

View on ClinicalTrials.gov More Proteinuric Kidney Disease trials